Literature DB >> 8289371

Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence.

H Horie1, S Koike, T Kurata, Y Sato-Yoshida, I Ise, Y Ota, S Abe, K Hioki, H Kato, C Taya.   

Abstract

Recombinant viruses between the virulent Mahoney and attenuated Sabin 1 strains of poliovirus type 1 were subjected to neurovirulence tests using a transgenic (Tg) mouse line, ICR-PVRTg1, that carried the human poliovirus receptor gene. The Tg mice were inoculated intracerebrally with these recombinant viruses and observed for clinical signs, histopathological lesions, and viral antigens as parameters of neurovirulence of the viruses. These parameters observed in the Tg mice were different for different inoculated viruses. Dose-dependent incidences of paralysis and of death were observed in the Tg mice inoculated with any viruses used. This indicates that values of 50% lethal dose are useful to score a wide range of neurovirulence of poliovirus. The neurovirulence of individual viruses estimated by the Tg mouse model had a strong correlation with those estimated by monkey model. Consequently, the mouse tests identified the neurovirulence determinants on the genome of poliovirus that had been identified by monkey tests. In addition, the mouse tests revealed new neurovirulence determinants, that is, different nucleotides between the two strains at positions 189 and 21 and/or 935 in the 5'-proximal 1,122 nucleotides. The Tg mice used in this study may be suitable for replacing monkeys for investigating poliovirus neurovirulence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289371      PMCID: PMC236503          DOI: 10.1128/JVI.68.2.681-688.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.

Authors:  S R Pollard; G Dunn; N Cammack; P D Minor; J W Almond
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Genetic analysis of the attenuation phenotype of poliovirus type 1.

Authors:  T Omata; M Kohara; S Kuge; T Komatsu; S Abe; B L Semler; A Kameda; H Itoh; M Arita; E Wimmer
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

4.  A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.

Authors:  M Kohara; S Abe; T Komatsu; K Tago; M Arita; A Nomoto
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

5.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants.

Authors:  H Toyoda; M Kohara; Y Kataoka; T Suganuma; T Omata; N Imura; A Nomoto
Journal:  J Mol Biol       Date:  1984-04-25       Impact factor: 5.469

6.  Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis.

Authors:  R B Ren; F Costantini; E J Gorgacz; J J Lee; V R Racaniello
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

7.  Transgenic mice susceptible to poliovirus.

Authors:  S Koike; C Taya; T Kurata; S Abe; I Ise; H Yonekawa; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

8.  Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.

Authors:  A Martin; D Benichou; T Couderc; J M Hogle; C Wychowski; S Van der Werf; M Girard
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

9.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

Authors:  R B Ren; E G Moss; V R Racaniello
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.

Authors:  A Nomoto; T Omata; H Toyoda; S Kuge; H Horie; Y Kataoka; Y Genba; Y Nakano; N Imura
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  37 in total

1.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

2.  Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; J Balanant; A Macadam; D Otelea; M Combiescu; A A Combiescu; R Crainic; F Delpeyroux
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.

Authors:  Franck B Riquet; Claire Blanchard; Sophie Jegouic; Jean Balanant; Sophie Guillot; Marie-Anne Vibet; Mala Rakoto-Andrianarivelo; Francis Delpeyroux
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

4.  Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.

Authors:  M Gromeier; L Alexander; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

5.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

6.  Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.

Authors:  A McGoldrick; A J Macadam; G Dunn; A Rowe; J Burlison; P D Minor; J Meredith; D J Evans; J W Almond
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor.

Authors:  Akiko Yanagiya; Seii Ohka; Noriyasu Hashida; Masahito Okamura; Choji Taya; Nobuhiko Kamoshita; Kuniko Iwasaki; Yukari Sasaki; Hiromichi Yonekawa; Akio Nomoto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Receptor (CD155)-dependent endocytosis of poliovirus and retrograde axonal transport of the endosome.

Authors:  Seii Ohka; Norie Matsuda; Koujiro Tohyama; Toshiyuki Oda; Masato Morikawa; Shusuke Kuge; Akio Nomoto
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Cell-dependent role for the poliovirus 3' noncoding region in positive-strand RNA synthesis.

Authors:  David M Brown; Steven E Kauder; Christopher T Cornell; Gwendolyn M Jang; Vincent R Racaniello; Bert L Semler
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.